Education
About Us
Working with TipRanks
Follow Us
Option Care Health Inc (OPCH)
NASDAQ:OPCH
OPCH Stock Chart & Stats
$31.60
-$0.14(-0.58%)
At close: 4:00 PM EST
$31.60
-$0.14(-0.58%)
Day’s Range― - ―
52-Week Range$24.24 - $36.80
Previous CloseN/A
Volume256.90K
Average Volume (3M)1.66M
Market Cap
$4.94B
Enterprise Value$4.83B
Total Cash (Recent Filing)$232.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)24.8
Beta0.33
Next Earnings
Apr 29, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding156,447,970
10 Day Avg. Volume2,060,866
30 Day Avg. Volume1,657,323
Financial Highlights & Ratios
PEG Ratio5.98
Price to Book (P/B)3.80
Price to Sales (P/S)0.89
P/FCF Ratio19.51
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit4.44
Enterprise Value/Ebitda10.39
Forecast
1Y Price Target
$39.56Price Target Upside25.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.87
Revenue Forecast (FY)$5.95B
Bulls Say, Bears Say
Bulls Say
Guidance And Operational PredictabilityCompany reiterated prior financial guidance and reported results in line with preannouncements, indicating predictable execution that can reduce volatility and support investor confidence.
Portfolio De-riskingMaterial reduction in reliance on a single therapy and disclosure that no single treatment dominates gross profit de-risks the product mix and supports more sustainable long-term revenue growth.
Share Repurchase CapacityBoard-approved expansion of the share repurchase authorization signals management confidence in cash flow and creates capacity for future buybacks that could bolster the stock.
Bears Say
Biosimilars And Pricing PressureEmerging biosimilar competition, shifts to subcutaneous treatments, and pricing changes tied to policy are expected to reduce gross profits and create sustained margin pressure.
Cash Flow And Inventory-driven ComparisonsCash flow from operations was characterized as somewhat disappointing and tougher comparisons after prior inventory-related boosts may soften near-term growth and constrain capital deployment.
Therapy-specific Headwind (Stelara)Anticipated revenue and gross profit headwind from Stelara is likely to pressure near-term results and could delay margin improvement unless offset by other product gains.
Option Care Health News
OPCH FAQ
What was Option Care Health Inc’s price range in the past 12 months?
Option Care Health Inc lowest stock price was $24.23 and its highest was $36.80 in the past 12 months.
What is Option Care Health Inc’s market cap?
Option Care Health Inc’s market cap is $4.94B.
When is Option Care Health Inc’s upcoming earnings report date?
Option Care Health Inc’s upcoming earnings report date is Apr 29, 2026 which is in 56 days.
How were Option Care Health Inc’s earnings last quarter?
Option Care Health Inc released its earnings results on Feb 24, 2026. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.468 by -$0.008.
Is Option Care Health Inc overvalued?
According to Wall Street analysts Option Care Health Inc’s price is currently Undervalued.
Does Option Care Health Inc pay dividends?
Option Care Health Inc does not currently pay dividends.
What is Option Care Health Inc’s EPS estimate?
Option Care Health Inc’s EPS estimate is 0.4.
How many shares outstanding does Option Care Health Inc have?
Option Care Health Inc has 156,447,970 shares outstanding.
What happened to Option Care Health Inc’s price movement after its last earnings report?
Option Care Health Inc reported an EPS of $0.46 in its last earnings report, missing expectations of $0.468. Following the earnings report the stock price went down -6.304%.
Which hedge fund is a major shareholder of Option Care Health Inc?
Currently, no hedge funds are holding shares in OPCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Option Care Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.56 (25.19% Upside)
$39.56 (25.19% Upside)
Blogger Sentiment
Bullish
OPCH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 845.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.67%
12-Months-Change
Fundamentals
Return on Equity
15.20%
Trailing 12-Months
Asset Growth
0.81%
Trailing 12-Months
Company Description
Option Care Health Inc
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
OPCH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a constructive operational and financial story: strong top-line growth, margin and automation gains, successful clinic and M&A integration, expanded pharma and payer partnerships, and a reaffirmation of 2026 guidance. Key near-term challenges include Stelara biosimilar-driven revenue and gross profit headwinds, a 2025 cash flow shortfall due to strategic inventory buys and elevated working capital needs, and persistent payer/market pressure. Management outlined concrete efficiency and cash-conversion actions and expects cash flow and EBITDA expansion in 2026, indicating confidence that headwinds are manageable.View all OPCH earnings summariesOPCH Stock 12 Month Forecast
Average Price Target
$39.56
▲(25.19% Upside)
Technical Analysis
Addus Homecare
―
Chemed
―
National Healthcare
―
Surgery Partners
―
Aveanna Healthcare Holdings
―
Ownership Overview
1.41% Insiders
39.25% Mutual Funds
17.51% Other Institutional Investors
15.58% Public Companies and
Individual Investors